Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 241

Similar articles for PubMed (Select 24692774)

1.
2.

Switching from Methylphenidate-Immediate Release (MPH-IR) to Methylphenidate-OROS (OROS-MPH): A Multi-center, Open-label Study in Korea.

Kim BN, Kim YN, Cheong US, Kim JW, Hwang JW, Shin MS, Cho SC; Korean OROS-MPH Study Group.

Clin Psychopharmacol Neurosci. 2011 Apr;9(1):29-35. doi: 10.9758/cpn.2011.9.1.29. Epub 2011 Apr 30.

3.

A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.

Soutullo C, Banaschewski T, Lecendreux M, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Bloomfield R, Squires LA, Coghill DR.

CNS Drugs. 2013 Sep;27(9):743-51. doi: 10.1007/s40263-013-0086-6.

4.

Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis.

Jain R, Babcock T, Burtea T, Dirks B, Adeyi B, Scheckner B, Lasser R.

Child Adolesc Psychiatry Ment Health. 2011 Nov 4;5(1):35. doi: 10.1186/1753-2000-5-35.

5.

The usefulness of Conners' Rating Scales-Revised in screening for attention deficit hyperactivity disorder in children with intellectual disabilities and borderline intelligence.

Deb S, Dhaliwal AJ, Roy M.

J Intellect Disabil Res. 2008 Nov;52(11):950-65. doi: 10.1111/j.1365-2788.2007.01035.x. Epub 2008 Jan 2.

PMID:
18179511
6.

Effects of long-term methylphenidate treatment: a pilot follow-up clinical and SPECT study.

Akay AP, Kaya GC, Emiroğlu NI, Aydin A, Monkul ES, Taşçi C, Miral S, Durak H.

Prog Neuropsychopharmacol Biol Psychiatry. 2006 Sep 30;30(7):1219-24. Epub 2006 Apr 17.

PMID:
16616981
7.

Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder.

Weiss M, Hechtman L, Turgay A, Jain U, Quinn D, Ahmed TS, Yates T, Reiz JL, Donnelly GA, Harsanyi Z, Darke AC.

J Child Adolesc Psychopharmacol. 2007 Oct;17(5):675-88.

PMID:
17979587
8.

Attention-deficit/hyperactivity disorder with obstructive sleep apnea: a treatment outcome study.

Huang YS, Guilleminault C, Li HY, Yang CM, Wu YY, Chen NH.

Sleep Med. 2007 Jan;8(1):18-30. Epub 2006 Dec 6.

PMID:
17157069
9.

Can we predict short-term side effects of methylphenidate immediate-release?

Karabekiroglu K, Yazgan YM, Dedeoglu C.

Int J Psychiatry Clin Pract. 2008;12(1):48-54. doi: 10.1080/13651500701435954.

PMID:
24916497
11.

Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.

Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fielbelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD.

Pediatrics. 2001 Jun;107(6):E105.

PMID:
11389303
12.

Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.

Wolff C, Alfred A, Lindermüller A, Rettig K, Mattejat F, Gerwe M, Slawik L, Schäuble B.

Curr Med Res Opin. 2011;27 Suppl 2:35-44. doi: 10.1185/03007995.2011.601733. Epub 2011 Jul 25.

PMID:
21787126
13.

[Factors affecting therapeutic effect of ADHD treated by optimal dose of methylphenidate].

Yang L, Wang YF.

Beijing Da Xue Xue Bao. 2007 Jun 18;39(3):284-8. Chinese.

14.
15.

Methylphenidate DAT binding in adolescents with Attention-Deficit/ Hyperactivity Disorder comorbid with Substance Use Disorder--a single photon emission computed tomography with [Tc(99m)]TRODAT-1 study.

Szobot CM, Shih MC, Schaefer T, Júnior N, Hoexter MQ, Fu YK, Pechansky F, Bressan RA, Rohde LA.

Neuroimage. 2008 Apr 15;40(3):1195-201. doi: 10.1016/j.neuroimage.2007.12.050. Epub 2008 Jan 10.

PMID:
18282769
16.

Open-label study of dexmethylphenidate hydrochloride in children and adolescents with attention deficit hyperactivity disorder.

Silva R, Tilker HA, Cecil JT, Kowalik S, Khetani V, Faleck H, Patin J.

J Child Adolesc Psychopharmacol. 2004 Winter;14(4):555-63.

PMID:
15662147
17.

Effects of combined treatment on Turkish children diagnosed with attention-deficit/hyperactivity disorder: a preliminary report.

Ercan ES, Varan A, Deniz U.

J Child Adolesc Psychopharmacol. 2005 Apr;15(2):203-19.

PMID:
15910205
18.

Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.

Spencer TJ, Greenbaum M, Ginsberg LD, Murphy WR.

J Child Adolesc Psychopharmacol. 2009 Oct;19(5):501-10. doi: 10.1089/cap.2008.0152.

19.

The rCBF brain mapping in adolescent ADHD comorbid developmental coordination disorder and its changes after MPH challenging.

Yeh CB, Huang WS, Lo MC, Chang CJ, Ma KH, Shyu JF.

Eur J Paediatr Neurol. 2012 Nov;16(6):613-8. doi: 10.1016/j.ejpn.2012.02.007. Epub 2012 Mar 13.

PMID:
22417719
20.

Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate.

Chou WJ, Chen SJ, Chen YS, Liang HY, Lin CC, Tang CS, Huang YS, Yeh CB, Chou MC, Lin DY, Hou PH, Wu YY, Liu HJ, Huang YF, Hwang KL, Chan CH, Pan CH, Chang HL, Huang CF, Hsu JW.

J Child Adolesc Psychopharmacol. 2012 Jun;22(3):215-25. doi: 10.1089/cap.2011.0006. Epub 2012 Apr 26.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk